Takeda closes South San Francisco R&D site in California restructuring
This article was originally published in Scrip
Takeda has decided to close a US research site in South San Francisco that was specialising in the discovery of antibody therapeutics, "relocating the most essential antibody and biologics research technologies and staff" to another existing facility in San Diego.
You may also be interested in...
The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.